Abilify Maintena News Today

The most important stories for you to know today

H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $22.00 and traded as low as $22.00. H. Lundbeck A/S shares last traded at $22.00, with a volume of 7,500 shares trading hands. H. […]

Shares of H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $22.00 and traded as low as $22.00. H. Lundbeck A/S shares last traded at $22.00, with a volume of 7,500 shares trading hands. H. […]

EVN (OTCMKTS:EVNVY – Get Free Report) and H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report) are both utilities companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Analyst Ratings This is a summary of current […]

Shares of H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $22.00 and traded as low as $22.00. H. Lundbeck A/S shares last traded at $22.00, with a volume of 7,500 shares traded. H. Lundbeck […]

Under Canada's Mental Health Act, doctors don’t have to get a patient’s consent for treatment — or the consent of a substitute decision maker. They have what’s known as the patient’s “deemed consent” to administer any treatment that’s been approved by the director of the mental health facility.

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap...

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace ...

H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report) fell 0% on Monday . The stock traded as low as $22.00 and last traded at $22.00. 7,500 shares traded hands during trading, an increase of 327% from the average session volume of 1,758 shares. The stock had previously closed at $22.01. Analyst Ratings Changes A number […]